Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Behaviors and Mental Disorders

Rare Diseases

Melanoma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Quality of Life

Neuroendocrine Tumor

Neuroepithelioma

This is a cross-sectional survey. Our main method of communication with patients will be email. Participants will complete a single online or telephone survey at a minimum of 12 months post initial treatment of checkpoint inhibitors and remain on maintenance therapy.

EuroQoL EQ-5D-3L

General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales

EORTC QLQ-C30

Additional potential immune-specific symptoms

PRO-CTCAE

Fatigue severity score questionnaire

Financial toxicity; satisfaction with ability to work

The COST

Physician information

Deborah Korenstein, MD

To identify and describe long-term quality of life (QOL) issues in patients with metastatic melanoma treated with checkpoint inhibitors who achieved cancer control for a minimum of 12 months and remain on maintenance checkpoint inhibitor therapy.

Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors

On the EQ-5D-3L, respondents are asked to indicate their health state by marking the box associated with the most appropriate statement in each of the 5 dimensions, resulting in a one digit number expressing the level (1-3) selected for that dimension from no problems to extreme problems.

Memorial Sloan Kettering Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors	NCT03326973	Metastatic Mela...	EuroQoL EQ-5D-3... EORTC QLQ-C30 PRO-CTCAE Fatigue severit... The COST Physician infor...	18 Years -	Memorial Sloan Kettering Cancer Center
Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors	NCT03326973	Metastatic Mela...	EuroQoL EQ-5D-3... EORTC QLQ-C30 PRO-CTCAE Fatigue severit... The COST Physician infor...	18 Years -	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for physician information